SCHEMBL8828012

SCHEMBL8828012

CC(Oc1ccccc1-c1nc(-c2ccccc2)ccc1-c1ccc(O)cc1)N1CCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 6/20 0.40
ADRA2B P18089 6/20 0.40
ADRA2C P18825 6/20 0.40
ALK Q9UM73 3/20 0.35
ALDH1A1 P00352 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HPGD P15428 3/20 0.34
HSD17B10 Q99714 3/20 0.34
KDM4E B2RXH2 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
S1PR1 P21453 1/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
MAOA P21397 3/20 0.33
MAOB P27338 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8808029 0.87 PTPN1 (0.37) ALKALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL8827945 0.76 ESR1 (0.40) ALDH1A1SMN1; SMN2HPGDHSD17B10MAPT
SCHEMBL8828015 0.75 KMT2A (0.41) ADRA2AADRA2BADRA2CALDH1A1SMN1; SMN2
SCHEMBL8827914 0.72 ALDH1A1 (0.38) ALKALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL27919055 0.70 MAPT (0.61) ALKALDH1A1HPGDHSD17B10MAPT
SCHEMBL8680387 0.68 MAPT (0.56) ALKALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL8808018 0.68 ESR1 (0.61) ALDH1A1HSD17B10KDM4ETSHRMAPT
SCHEMBL8827929 0.68 GRIA1 (0.39) ALKALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL8676997 0.65 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2HPGDHSD17B10KDM4E
SCHEMBL12854117 0.65 RAB9A (0.54) ALDH1A1SMN1; SMN2HPGDKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5672609-A POSTMENOPAUSAL SYNDROME; ANTILIPEMIC AND -CARCINOGENIC AGENTS; OSTEOPOROSIS; CARDIOTONIC AGENTS; RESTENOSIS; SIDE EFFECT REDUCTION COMPARED TO ESTROGEN ELI LILLY AND COMPANY (US) 1997-09-30 US claimed